These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8120733)

  • 1. USP perspectives on particle contamination of injectable products.
    Gallelli JF; Groves MJ
    J Parenter Sci Technol; 1993; 47(6):289-92. PubMed ID: 8120733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particulate-matter content of 11 cephalosporin injections: conformance with USP limits.
    Parkins DA; Taylor AJ
    Am J Hosp Pharm; 1987 May; 44(5):1111-8. PubMed ID: 3605122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of improved standardization methods and instrumentation in the USP particulate test for SVI.
    Barber TA; Lannis MD; Williams JG; Ryan JF
    J Parenter Sci Technol; 1990; 44(4):185-203. PubMed ID: 2213427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of methods for detection of particulate matter in large-volume perenterals.
    Blanchard J; Thompson CM; Schwartz JA
    Am J Hosp Pharm; 1976 Feb; 33(2):144-50. PubMed ID: 1258874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new coincidence model for single particle counters, Part I: Theory and experimental verification.
    Knapp JZ; Abramson LR
    J Pharm Sci Technol; 1994; 48(3):110-34. PubMed ID: 8069513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of acceptance criteria for particulate limits for small-volume parenteral products.
    Tsuji K; Lewis AR
    J Pharm Sci; 1978 Jan; 67(1):50-5. PubMed ID: 619115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Particulate contamination in parenterals: current issues.
    Groves MJ
    Boll Chim Farm; 1991 Oct; 130(9):347-54. PubMed ID: 1799429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. II. Particulate matter levels in large-volume injections: USP XIX method.
    Wente MA
    Bull Parenter Drug Assoc; 1977; 31(4):165-9. PubMed ID: 890179
    [No Abstract]   [Full Text] [Related]  

  • 9. Particulate-matter content of D5/NS for injection: manufacturer difference and conformance with USP limits.
    Smith JK; Baumann RR; Gunning WT; Annancy L; Alexander KS
    J Parenter Sci Technol; 1988; 42(6):180-6. PubMed ID: 3273493
    [No Abstract]   [Full Text] [Related]  

  • 10. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 11. Method evaluation: automated microscopy as a compendial test for particulates in parenteral solutions.
    Barber TA; Lannis MD; Williams JG
    J Parenter Sci Technol; 1989; 43(1):27-47. PubMed ID: 2926604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 13. Cleanliness assessment of supplier-cleaned stoppers.
    Townsend MW; Conti B; Hazrati A; DeLuca PP
    J Parenter Sci Technol; 1989; 43(2):98-102. PubMed ID: 2709242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Particulate matter in four reconstituted cephalosporin injections.
    Kilarski DJ; Visconti JA; Frank SG
    Am J Hosp Pharm; 1983 Apr; 40(4):619-23. PubMed ID: 6846372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Particulate matter in parenteral products: a review.
    Borchert SJ; Abe A; Aldrich DS; Fox LE; Freeman JE; White RD
    J Parenter Sci Technol; 1986; 40(5):212-41. PubMed ID: 3540253
    [No Abstract]   [Full Text] [Related]  

  • 16. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches to reducing subvisible particle counts in lyophilized parenteral formulations.
    Gupta PK; Porembski E; Williams NA
    J Pharm Sci Technol; 1994; 48(1):30-7. PubMed ID: 8004415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Particulate evaluation of parenteral nutrition solutions by electronic particle counting and scanning electron microscopy.
    Akers MJ; Schrank GD; Russell S
    Am J Hosp Pharm; 1981 Sep; 38(9):1304-7. PubMed ID: 6792911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection.
    Hung JC
    J Nucl Med; 2002 Nov; 43(11):1495-506. PubMed ID: 12411554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parametric two-stage sequential quality assurance test of dose content uniformity.
    Tsong Y; Shen M
    J Biopharm Stat; 2007; 17(1):143-57. PubMed ID: 17219760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.